- Home
- ANEB vs NXTC Comparison
ANEB vs NXTC Comparison
Compare ANEB & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- NXTC
- Stock Information
- Founded
- ANEB 2020
- NXTC 2015
- Country
- ANEB United States
- NXTC United States
- Employees
- ANEB N/A
- NXTC N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- NXTC Health Care
- Exchange
- ANEB Nasdaq
- NXTC Nasdaq
- Market Cap
- ANEB 36.7M
- NXTC 40.3M
- IPO Year
- ANEB 2021
- NXTC 2019
- Fundamental
- Price
- ANEB $1.46
- NXTC $1.19
- Analyst Decision
- ANEB Buy
- NXTC Strong Buy
- Analyst Count
- ANEB 1
- NXTC 2
- Target Price
- ANEB $8.00
- NXTC $4.00
- AVG Volume (30 Days)
- ANEB 6.3K
- NXTC 41.7K
- Earning Date
- ANEB 11-13-2024
- NXTC 11-07-2024
- Dividend Yield
- ANEB N/A
- NXTC N/A
- EPS Growth
- ANEB N/A
- NXTC N/A
- EPS
- ANEB N/A
- NXTC N/A
- Revenue
- ANEB N/A
- NXTC N/A
- Revenue This Year
- ANEB N/A
- NXTC N/A
- Revenue Next Year
- ANEB N/A
- NXTC N/A
- P/E Ratio
- ANEB N/A
- NXTC N/A
- Revenue Growth
- ANEB N/A
- NXTC N/A
- 52 Week Low
- ANEB $1.25
- NXTC $1.03
- 52 Week High
- ANEB $3.30
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- ANEB 36.57
- NXTC 37.32
- Support Level
- ANEB $1.25
- NXTC $1.28
- Resistance Level
- ANEB $1.68
- NXTC $1.40
- Average True Range (ATR)
- ANEB 0.16
- NXTC 0.09
- MACD
- ANEB -0.01
- NXTC -0.01
- Stochastic Oscillator
- ANEB 30.00
- NXTC 6.82
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.